In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.

International Journal of Antimicrobial Agents

Volumn 31, Issue 2, 2008, Pages 171-174

  Córdoba, Susana ^a   Rodero, Laura ^b   Vivot, Walter ^a   Abrantes, Rubén ^a   Davel, Graciela ^a   Vitale, Roxana G ^a,c,d  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^b PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

Author keywords

Antifungal interactions; Antifungal susceptibility; Fusarium spp.

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG POTENTIATION; FUNGUS ISOLATION; FUSARIUM; FUSARIUM DECELNICELLULARE; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SPECIES IDENTIFICATION; STRAIN IDENTIFICATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; FUSARIUM; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PYRIMIDINES; TRIAZOLES;

EID: 37549065141     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.09.005     Document Type: Article

References (18)

1. Dignani M.C., and Anaissie E. Human fusariosis. Clin Microbiol Infect 10 Suppl.1 (2004) 67-75
2. Boutati E.I., and Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood 90 (1997) 999-1008
3. Torres H.A., and Kontoyiannis D.P. Hyalohyphomycoses. In: Dismukes W.E., Pappas P.G., and Sobel J.D. (Eds). Oxford textbook of clinical mycology (2003), Oxford University Press, New York 252-270
4. Ortoneda M., Capilla J., Javier Pastor F., Pujol I., and Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 48 (2004) 69-71
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A. Wayne, PA: NCCLS; 2002.
6. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52 (2003) 1
7. Fleming R.V., Walsh T.J., and Anaissie E.J. Emerging and less common fungal pathogens. Infect Dis Clin North Am 16 (2002) 915-933 vi-vii
8. Arikan S., Lozano-Chiu M., Paetznick V., Nangia S., and Rex J.H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 37 (1999) 3946-3951
9. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 (1999) 501-517
10. Polak A. Combination therapy with antifungal drugs. Mykosen Suppl 2 (1988) 45-53
11. Vagace J.M., Sanz-Rodriguez C., Casado M.S., Alonso N., Garcia-Dominguez M., de la Llana F.G., et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis 7 (2007) 40
12. Durand-Joly I., Alfandari S., Benchikh Z., Rodrigue M., Espinel-Ingroff A., Catteau B., et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 41 (2003) 4898-4900
13. Pujol I., Guarro J., Sala J., and Riba M.D. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B against Fusarium. Antimicrob Agents Chemother 41 (1997) 808-811
14. Groll A.H., Piscitelli S.C., and Walsh T.J. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 21 (2001) 133S-148S
15. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., de la Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
16. Te Dorsthorst D.T., Verweij P.E., Meis J.F., Punt N.C., and Mouton J.W. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother 46 (2002) 702-707
17. Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47 (2003) 106-117
18. Margalith P.Z. Steroid microbiology (1986), Charles C. Thomas, Springfield, IL